Emory University was awarded a $586,875 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2026 to elucidate and exploit SAMHD1 for breast cancer therapy. Through this funding, Emory University researchers will investigate medical solutions for breast cancer by exploring the role of the SAMHD1 protein and developing new therapeutic approaches for...
Emory University was awarded a $586,875 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2026 to elucidate and exploit SAMHD1 for breast cancer therapy. Through this funding, Emory University researchers will investigate medical solutions for breast cancer by exploring the role of the SAMHD1 protein and developing new therapeutic approaches for...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The Defense Health Agency awarded Emory University a $305,175 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel therapeutic target for renal medullary carcinoma. The award period runs from July 1, 2023 to June 30, 2026. As a leading research university, Emory has a strong track record of delivering scientific research and public health services under federal grants and contracts. This award supports Emory's expertise in...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $525,799 to the University of Alabama for a 3-year period from September 1, 2025 to August 31, 2028. The funding supports research aimed at "TARGETING GPNMB TO IMPROVE EFFICACY OF CDK4/6 INHIBITORS IN ER+ BREAST CANCER". The University of Alabama, through its Office for Sponsored Programs Division, will conduct advanced biomedical research...
Emory University will conduct research under a $1,255,611 Project Grant from the Defense Health Agency through the Military Medical Research and Development program. The three-year award beginning in April 2023 will fund research to define the molecular basis for immunogenicity of locally advanced prostate tumors resistant to androgen deprivation therapy. The CFDA 12.420 program supports basic, applied and advanced biomedical research to transform military and public health care through...
This federal Project Grant award, valued at $1,201,500.00 and awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research focused on the targeting of IGF1R and IR-A in hormone receptor-positive breast cancer using natural killer cell-mediated approaches. The award was granted to the Regents of the University of Minnesota, a prominent land-grant research institution, with a performance period from...
This Project Grant, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $625,994 to Emory University to support research on novel cell therapy approaches for neuroblastoma. The project aims to advance the development of new treatments for this type of pediatric cancer, which is a priority area for military medical research. Emory University, a leading academic research institution, is well-positioned to conduct this work,...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...